Johnson & Johnson posted a Q4 revenue beat over consensus estimates and delivered EPS that modestly topped forecasts. Management accompanied the release with a robust full-year 2026 guidance, projecting continued top- and bottom-line growth driven by strength in immunology, oncology and medical devices.

Despite the positive results and guidance, shares held flat on the day, reflecting a valuation that already incorporates last year’s over 40% rally and a further 5% gain year to date. Jim Cramer highlighted the stock’s resilience, labeling J&J “irrepressible” and noting its relative affordability versus broader market peers.